We demonstrate multiple advantages of using QCCs in CML routine quantitative BCR-ABL1 monitoring e.g. as to decide when experiments should be rejected while at the same time avoiding false alarm situations. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.